Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance
Shepeng Wei1, Xuxu Xu1, Jing Bao1
1Department of Neurosurgery, Shidong Hospital, University of Shanghai for Science and Technology Shanghai China.
Medcomm
|April 3, 2026
Summary
Isocitrate dehydrogenase (IDH)-mutant astrocytomas require personalized treatment. This review synthesizes molecular classification, risk models, and therapies, emphasizing IDH inhibition and novel strategies for improved outcomes.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Genomics
Background:
- Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent a heterogeneous molecular entity across CNS WHO Grades 2-4.
- Prognostic heterogeneity persists despite integrated grading, necessitating advanced risk stratification beyond grade alone.
- Early genetic alterations (IDH1/2, ATRX, TP53) and late events (e.g., CDKN2A/B deletion) influence clinical behavior.
Purpose of the Study:
- To review contemporary molecular classification and diagnostic principles for IDH-mutant astrocytomas.
- To synthesize pragmatic risk models integrating clinical, histomolecular, and imaging/radiomics data.
- To outline standard and emerging therapeutic strategies, resistance mechanisms, and future research directions.
Main Methods:
- Comprehensive literature review of molecular classification, diagnostic principles, and risk stratification models.
- Synthesis of current standard therapies (surgery, radiotherapy, chemotherapy) within a risk-adapted framework.
- Analysis of emerging therapeutic advances, resistance mechanisms, and future trial designs.
Main Results:
- Multidomain risk stratification, integrating clinical, histomolecular, and radiomic features, improves prognostic accuracy.
- Brain-penetrant IDH inhibitors (e.g., vorasidenib) represent a significant therapeutic advance.
- Emerging strategies include vaccines, epigenetic modulation, and targeting the tumor microenvironment.
Conclusions:
- A trajectory-based paradigm prioritizing neurocognitive preservation and patient-reported outcomes is crucial.
- Durable disease control across long-term survivorship requires a combination of risk-adapted therapies and novel agents.
- Future research should focus on biomarker-driven monitoring and innovative trial designs for IDH-mutant astrocytomas.
